← Back to Screener
Spruce Biosciences, Inc. Common Stock (SPRB)
Price$50.43
Value ScoreD
Growth ScoreF
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-57.50%
Price vs S&P 500 (4W)-10.73%
VGM Score32.80
Market Capitalization$138.80M
All Metrics
Book Value / Share (Quarterly)$24.82
P/TBV (Annual)0.84x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-20.98
Price vs S&P 500 (YTD)-50.27%
Net Profit Margin (TTM)-1079.94%
EPS (TTM)$-38.47
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-38.47
EPS (Annual)$-50.65
ROI (Annual)-90.70%
Cash / Share (Quarterly)$39.47
ROA (Last FY)-73.58%
Revenue Growth TTM (YoY)-90.18%
EBITD / Share (TTM)$-35.25
ROE (5Y Avg)-88.29%
Operating Margin (TTM)-1143.37%
Cash Flow / Share (Annual)$-24.09
P/B Ratio4.08x
P/B Ratio (Quarterly)2.64x
Net Income / Employee (Annual)$-4,875,000
EV / Revenue (TTM)18.57x
Net Interest Coverage (TTM)-432.33x
ROA (TTM)-102.14%
EPS Incl Extra (Annual)$-50.65
Current Ratio (Annual)5.20x
Quick Ratio (Quarterly)4.51x
3-Month Avg Trading Volume0.06M
52-Week Price Return933.40%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.10
P/S Ratio (Annual)28.26x
Asset Turnover (Annual)0.11x
52-Week High$240.00
EPS Excl Extra (Annual)$-50.65
26-Week Price Return-49.57%
Quick Ratio (Annual)5.17x
13-Week Price Return-6.23%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.58x
Enterprise Value$91.18M
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)36.74%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1079.21%
Cash / Share (Annual)$35.70
3-Month Return Std Dev91.69%
Net Income / Employee (TTM)$-4,660,000
ROE (Last FY)-90.70%
Net Interest Coverage (Annual)-435.44x
EPS Basic Excl Extra (Annual)$-50.65
Total Debt / Equity (Quarterly)0.18x
EPS Incl Extra (TTM)$-38.47
ROI (TTM)-142.93%
P/S Ratio (TTM)28.26x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.90
Price vs S&P 500 (52W)909.04%
Year-to-Date Return-42.11%
5-Day Price Return-0.53%
EPS Normalized (Annual)$-50.65
ROA (5Y Avg)-64.97%
Net Profit Margin (Annual)-1079.21%
Month-to-Date Return-1.64%
Cash Flow / Share (TTM)$-1.43
EBITD / Share (Annual)$-48.03
Operating Margin (Annual)-1140.30%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-84.47%
LT Debt / Equity (Quarterly)0.16x
EPS Basic Excl Extra (TTM)$-38.47
P/TBV (Quarterly)0.68x
P/B Ratio (Annual)2.22x
Pretax Margin (TTM)-1079.94%
Book Value / Share (Annual)$30.66
Price vs S&P 500 (13W)-14.48%
Beta3.37x
Revenue / Share (TTM)$0.00
ROE (TTM)-154.70%
52-Week Low$4.35
vGradeD
gGradeF
mGradeB
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-8.94est. -8.99
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.10
4.30
4.30
4.27
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SPRBSpruce Biosciences, Inc. Common Stock | D | F | B | $50.43 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Spruce Biosciences is a late-stage biopharmaceutical company developing therapies for rare endocrine disorders with significant unmet medical needs. Its pipeline includes Tralesinidase Alfa (TA-ERT) and Tildacerfont/Cortibon, a companion diagnostic co-developed with HMNC Brain Health. The company targets underserved patient populations through specialized therapeutic solutions.